BENLYSTA

BENLYSTA is a prescription biologic therapy from GSK for people living with active systemic lupus erythematosus (SLE) or active lupus nephritis, a kidney inflammation related to lupus. Approved for adults and children aged 5 years and older, it is used as an add-on to other lupus medicines. BENLYSTA targets an underlying cause of lupus and is not a steroid; the brand notes that it does not suppress the entire immune system. It is available for administration under the skin at home or by intravenous infusion, with the appropriate option discussed with a healthcare professional.

The brand’s website offers information about lupus and lupus nephritis, how BENLYSTA works, treatment and administration, potential side effects, and conversations with care teams. It also provides patient and care-partner resources, videos, FAQs, and real patient stories. Eligible commercially insured patients may be able to access the BENLYSTA Copay Program for eligible out-of-pocket costs, subject to program terms and annual maximums.